

# Epidemiological and Clinical Factors Associated with Spontaneous Clearance of Hepatitis C Virus

Wahiba Guenifi<sup>1,\*</sup> Abdelkader Gasmi<sup>1</sup>, Abdelmadjid Lacheheb<sup>1</sup>

<ol> <li>Department of infectious diseases, Faculty of medicine, University FERHAT Abbes, Setif 1-Algeria</li> </ol>	ABSTRACT BACKGROUND The risk of chronicity is high after acute hepatitis C. The infection remains limited and spontaneously resolves in an average of 30% of subjects. Such subjects are considered recovered and do not require any medical care. This study aims to evaluate the epidemio-
	logical and clinical factors associated with spontaneous viral clearance. METHODS We conducted a descriptive retrospective study on patients' files managed for a posi- tive hepatitis C serology who benefited from the research of serum viral RNA by molecu- lar biology
	RESULTS The study collected 429 usable files. The mean age of the patients was 50.21 years, and the sex ratio was 0.98. Spontaneous viral clearance was estimated at 17.2%. The univari- ate analysis showed that clearance was significantly greater in subjects under the age of 50 years, patients without type 2 diabetes, patients co-infected with hepatitis B virus, patients with transfusion, and those diagnosed fortuitously. Multivariate analysis confirmed the relationship between diabetes and the circumstances of the diagnosis. The relationship in the case of hepatitis B co-infection was very close to the statistical significance level (p=0.055).
*	CONCLUSION The presence of hepatitis B co-infection in patients with positive hepatitis C serology predicts a high probability of having spontaneous clearance. However, advanced age and the existence of a history of blood transfusion, type 2 diabetes or suggestive signs of liver damage are associated with persistent viremia
<sup>*</sup> Corresponding Author: Wahiba Guenifi, PhD Address : Department of infectious dis- eases, Faculty of medicine, University FERHAT Abbes, Setif 1-Algeria	KEYWORDS: Hepatitis C virus; Spontaneous clearance; Diabetes; Diagnostic circumstances; Hepa- titis B co-infection
Tel : 00213667339852 Fax : 0021336721637 Email : o.guenifi@univ-setif.dz Received : 19 Aug. 2020 Accepted : 28 Jan. 2021	Please cite this paper as: Guenifi W, Gasmi A, Lacheheb A. Epidemiological and Clinical Factors Associated with Spontaneous Clearance of Hepatitis C Virus. Middle <i>East J Dig Dis</i> 2021; <b>13</b> : 321-327. doi: 10.34172/mejdd.2021.241
■福昌 ○ 2021 The A	Author(s). This work is published by Middle East Journal of Digestive Diseaes as an open access

article distributed under the terms of the Creative Commons Attribution License (https://creativecommons. org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.

# 322 Epidemiological and Clinical Factors Associated

## **INTRODUCTION**

LiHepatitis C virus (HCV) is a hepatotropic virus that can cause serious chronic infections in humans. Virus contamination results from exposure to blood that occurs during blood transfusion (become less frequent since the systematic screening of blood donors), risky medical care (during hospitalization, surgery, endoscopic exploration, etc.), traumatic sexual intercourse, injection drug use, or from mother to child. The distribution of viral hepatitis C (VHC) is ubiquitous; about 130 to 150 million people are chronically infected. The most affected regions are Africa, Central Asia, and East Asia. In Algeria, the prevalence of anti-HCV antibodies in the general population is on average 1%.<sup>1,2</sup>

After an acute VHC infection, the risk of progression to chronicity is approximately 60-85%. The infection is limited and spontaneously progresses to resolution in 30% of the subjects. This healing is affirmed by the presence of HCV antibodies and the absence of serum viral RNA. Such subjects are considered cured and do not require medical treatment.

Spontaneous viral clearance (SVC) usually occurs within 3 to 12 months of infection (16.5 weeks on average). According to a meta-analysis that included six studies involving 998 individuals, the occurrence of SVC in the 3, 6, 12, and 24 months after infection was 19.8%, 27.9%, 36.1%, and 37.1%, respectively.<sup>3,4</sup>

The asymptomatic nature of acute VHC makes its diagnosis difficult and its evolution poorly studied. Factors associated with SVC are poorly understood; however, several factors appear to be involved: host factors such as sex and immune response (T lymphocyte response: CD4 + T lymphocytes as key regulators and CD8 + T lymphocytes as major antiviral effectors), viral factors such as genotype, and genetic factors such as genotype of interleukin-28B and some alleles of the HLA system .<sup>3,5,6,7,8,9,10</sup>

SVC is rare but possible in the chronic hepatitis phase.<sup>11</sup> It has been reported following liver transplantation, development of hepatocellular carcinoma, or stopping immunosuppressive therapy. It has also been reported during pregnancy, after superinfection with hepatitis B virus (HBV)<sup>12,13,14,15</sup> and after immune restoration in patients infected with human immunodeficiency virus (HIV).<sup>10,16,17,18</sup>

The objective of this study is to look for epidemiological and clinical factors that may be associated with SVC in Sétif, Algeria.

#### MATERIALS AND METHODS

We conducted a retrospective descriptive study on patient files treated in the Department of Infectious Diseases of the University Hospital of Setif-Algeria, between January 2000 and December 2019, for a positive hepatitis C serology and benefited from serum viral RNA research by molecular biology. An undetectable serum viral RNA was checked regularly by a second sample 2 to 3 months later.

As this is a retrospective study, authorization to access the files was obtained from the head doctor of the Department.

All the data collected from the files were initially entered in Excel, and statistical analyses were performed using SPSS software for Windows version 18.0 and considered:

- A descriptive study of all the epidemiological and clinical variables available in the files:

o Sex

o Age at the time of discovery of positive HCV serology

o Medical history

 Potential contamination factors: transfusion, surgery, endoscopic exploration, similar case in the family surrounding, blood exposure accident (BEA), tattooing or scarification, intreveneous drug addiction, and dental care.

o Associated co-morbidities: diabetes, arterial hypertension, chronic hemodialysis, thyroid disorders, coinfection with HBV and/or HIV, overweight, consumption of alcohol and/or tobacco, etc.

- We excluded 45 files due to two or more missing data

- An analysis of the factors associated with an SVC in univariate then in multivariate by logistic regression. The statistical test was Chi-square for percentages. Odds ratios (OR) are shown with 95% confidence intervals (CI); the significance threshold was set at 5%. The variables included in multivariate analysis are those with a significant relationship in univariate analysis.

#### RESULTS

The study collected 429 usable files. Descriptive analysis of the population studied found a mean age of 50.21 years [4 to 86 years old], a median of 52 years old, and a sex ratio, males to females, of 0.98. The discovery of HCV was fortuitously made by routine blood tests (preop-

Variables		Spontaneous viral clear- ance: N (%)	No spontaneous viral clearance: N (%)	OR [IC à 95%]	p ( <b>X2</b> )	
Age at the time of di-	< 50	43 (22.6)	147 (77.4)	1•96		
agnosis (years old)	> 50	31 (13.0)	208 (87.0)	[1.18-3.26]	0.006 (6.92)	
Diagnostic circumstances	Fortuitous	71 (21.3)	262 (78.7)	8.40		
	Presence of suggestive signs of liver injury	3 (3.1)	93 (96.9)	[2.58-27.32]	<1/1000 (17.2)	
Type 2 diabetes	Yes	8 (8.6)	85 (91.4)	0.39	0.007 (6.22)	
	No	66 (19.6)	270 (80.4)	[0.18-0.83]		
Blood transfusion	Yes	33 (23.4)	108 (76.6)	1.84	0.014 (5.57)	
	No	41 (14.2)	247 (85.8)	[1.10-3.07]	0.014 (5.57)	
	Yes	10 (38.5)	16 (61.5)	3.31		
HBV co-infection	No	64 (15.9)	339 (84.1)	[1.44-7.62]	0.007 (8.73)	

Table 1: Variables associated with spontaneous viral clearance in univariate analysis

erative, pregnancy, employment, etc.) or screening around a case in 333 patients (77.6%); the diagnosis was made on clinical or paraclinical signs suggestive of liver injury in 96 patients (22.4%). Decompensation of cirrhosis revealed the disease in 27 patients.

Iatrogenic risk factors were frequent and varied in patients: surgery (264 patients), blood transfusion (141 patients), previous hospitalization (311 patients), endoscopy (120 patients), BEA (34 patients), scarification or tattooing (109 patients), intravenous drug abuse (4 patients), risky sexual behavior (9 patients), and dental care (366 patients from 391 data collected). The presence of VHC in the family surrounding was found 23 times, and only three partners had a positive HCV serology.

Co-morbidities were frequent and sometimes multiple in the same patient. Arterial hypertension (165 cases), type 2 diabetes (93 cases), chronic hemodialysis (74 cases), thyroid disorders (37 cases), bronchial asthma (32 cases), and overweight estimated by a body mass index (BMI) greater than 25 kg/m<sup>2</sup> (131 cases from 293 data collected). Alcohol and tobacco consumption were found in 12 and 65 cases, respectively.

26 patients had positive HBs Ag, and four patients were

infected with HIV. No patient had HCV-HBV-HIV co-infection or syphilis serology positive.

Other pathologies such as respiratory diseases, hematological diseases, or inflammatory diseases were found in 86 patients.

The SVC rate was estimated at 17.2% (74 cases) with a 95% CI of [14.0-20.7]. Univariate analysis showed that SVC is significantly greater in subjects less than 50 years of age, patients without type 2 diabetes, patients co-infected with HBV, people receiving transfusions, and those diagnosed fortuitously (table 1). No association was found for the other variables.

Multivariate analysis confirmed the relationship of SVC with the circumstances of diagnosis and diabetes. The relationship with HBV co-infection was very close to the significance level: p=0.055 (table 2).

#### DISCUSSION

To the authors' knowledge, this is the first study assessing the factors associated with SVC after HCV contamination in Algeria.

Several results characterize our study: besides the importance of iatrogenic risk factors in our region, their

# 324 Epidemiological and Clinical Factors Associated

				unuiyon	
В	S.E	Wald	Df	Sig.	Exp (B)
.292	.282	1.070	1	.301	1.339
1.968	.609	10.453	1	.001	7.158
.833	.417	3,982	1	.046	2.299
211	.279	.570	1	.450	.810
861	.449	3.677	1	.055	.423
-3.212	.829	14.995	1	.000	
	B .292 1.968 .833 211 861	B         S.E           .292         .282           1.968         .609           .833         .417          211         .279          861         .449	B         S.E         Wald           .292         .282         1.070           1.968         .609         10.453           .833         .417         3,982          211         .279         .570          861         .449         3.677	B         S.E         Wald         Df           .292         .282         1.070         1           1.968         .609         10.453         1           .833         .417         3.982         1          211         .279         .570         1          861         .449         3.677         1	.292         .282         1.070         1         .301           1.968         .609         10.453         1         .001           .833         .417         3,982         1         .046          211         .279         .570         1         .450          861         .449         3.677         1         .055

#### Table 2: Variables associated with spontaneous viral clearance in multivariate analysis

multiplicity in the same patient is frequent. Indeed, among 264 patients who underwent surgery, 109 patients were transfused, and 82 patients underwent endoscopic exploration, but intravenous drug addiction (a major risk factor in high-income countries and increasingly common in low- and middle-income countries <sup>5,19,20</sup>) has only been found in four patients. This means that the fight against transmission in health care remains a key element in the elimination of the disease in our region.

The importance of co-morbidities is linked to the type of study (real-life data). Among 163 patients with arterial hypertension in this series, 58 had diabetes, and 49 were receiving chronic hemodialysis. This element leads to more severe disease and may hamper therapy in viremic patients.

The circumstances of the diagnosis (fortuitous in more than <sup>3</sup>/<sub>4</sub> of the patients) and the lower age at the discovery of the disease (less than 50 years old) are common during VHC. They are due to the silent nature of the disease over several decades.<sup>21</sup>

The prevalence of SVC estimated at 17.2% with a 95% CI [14.0-20.7] appears smaller than the reported mean (30%), but it remains within the range theoretically reported,<sup>21</sup> for example, Alter had reported a rate of 14% while Rodger had found a rate of 46%.<sup>22,23</sup>

The majority of factors associated with SVC found in our study are in agreement with the literature:

## SVC and epidemiological factors

Most studies report that women are more likely to clear the virus spontaneously than men. This finding has not been explained yet<sup>3,4,5,10,24</sup> However, some studies have found a result similar to ours (lack of relationship between sex and SVC).<sup>25</sup> Hormonal genetic variations appear related to SVC. A Chinese study evaluated the consequences of genetic variants of the estrogen receptor  $\alpha$  (ER $\alpha$ ) on the course of the disease and found that the genotype "ESR2 rs4986938 AA" of ER $\alpha$  would be associated with SVC.<sup>26</sup>

As this is a retrospective study unable to study the age of contamination, we studied the age at the time of the diagnosis of the infection. The results of a greater SVC in case of early discovery of a positive serology (p=0.006; OR: 1.96 [1.18-3.26]) in the univariate analysis could be correlated with the results of prospective studies, which had found that the probability of an SVC was higher when the contamination was early.<sup>3,25</sup> Other studies have shown that the risk of cirrhosis is more important when contamination occurs in old age.<sup>27</sup> Similarly, the natural history of HCV explains the positive relationship found between diagnostic circumstances and SVC (only three cases were not viremic among symptomatic patients: p<0.001). It is well established that clinical signs regress and transaminases become normal after virus elimination.<sup>21</sup>

Regarding the mode of contamination, a significantly greater SVC in transfused patients found in the univariate analysis should be interpreted with caution because of the retrospective nature of the study and the multiplicity of risk factors in the population studied. Indeed, among 141 patients transfused, 135 had at least two risk factors, and 109 had three or more factors. The result found in multivariate would be more probable. We did not find any study comparing SVC according to the modes of contamination in the literature; the percentage of SVC after transfusion is usually between 15% to 20%.<sup>28,29,30</sup> while a study carried out on women contaminated after injection of anti-D found a significantly higher rate (45%).<sup>31</sup>

*Guenif et al.* 325

#### SVC and clinical factors

HBV/HCV co-infection is not rare in areas where HBV endemicity is high due to the same modes of transmission. A greater SVC in the case of HBV co-infection (p= 0.007 in univariate and p=0.055 in multivariate analysis) has also been reported by several studies. It would be due to mutual interference. There is probably a biological interaction between HBV and the response of specific HCV T cells leading to the production of interferons that could trigger a suppressive effect on HCV infection.<sup>3,14,15,25,32</sup>

In contrast, in the case of HIV co-infection, there is a deleterious influence of HIV on liver disease leading to a rapid progression of liver damage and an increase of HCV viral load. SVC is not frequent, and viremia increases gradually as advancing immunosuppression.<sup>24,33,34</sup> A few cases of SVC in chronic HCV have been reported after immune recovery under antiretroviral therapy.<sup>16,17,18,35</sup> The small number of HIV-infected patients of our series does not allow us to draw any conclusions. Also, in hemodialy-sis patients, SVC is not usual and occurs in approximately 5% of cases. This is due to a failure of the adaptive immune system, such as the absence of significant responses of T cells and antibodies.<sup>8,36,37,38</sup>

The first descriptions of diabetes/HCV association date back to the 1990s. Several studies from different parts of the world have reported that HCV can contribute to the development of diabetes mellitus. A higher prevalence of type 2 diabetes was observed in patients infected with HCV than in those with other forms of chronic hepatitis. Rouabhia found a higher prevalence of type 2 diabetes in VHC compared with VHB (39.1% vs. 5%; *p*<0.0001). The course of the infection in cases of diabetes is characterized by advanced lesions of fibrosis and cirrhosis.<sup>39,40</sup> This explains our result; only 8.6% of diabetics against 19.6% of non-diabetic patients had spontaneously eliminated the virus (*p*<0.05).

#### **CONCLUSION**

In patients with positive HCV serology, The presence of hepatitis B co-infection in patients with positive hepatitis C serology predicts a high probability of having spontaneous clearance. However, advanced age and the existence of a history of blood transfusion, type 2 diabetes or suggestive signs of liver damage are associated with persistent viremia.

The fight against iatrogenic transmission of HCV remains essential for the elimination of the disease in our country.

Despite the positive results of this retrospective study, prospective studies analyzing all the factors (host, viral, and genetic factors) are needed in order to overcome the shortcomings of retrospective studies represented mainly by a lack of several data in the files.

## ETHICAL APPROVAL

There is nothing to be declared.

#### CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

#### REFERENCES

- World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: WHO; 2018. https://www.who.int/hepatitis/ publications/hepatitis-c-guidelines-2018/en/
- Laurain A, Vallet-Pichard A, Corouge M, Pol S. Hépatites virales. *EMC - Maladies infectieuses* 2016 Mai. 13(2). doi : 10.1016/S1166-8598(16)61448-5
- Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors—A systematic review and meta-analysis. J Viral Hepat 2018;00:1-19. doi.org/10.1111/jvh.12866.
- Grebely J, Page K, Sacks-Davis R, Van Der Loeff MS, Rice TM, Bruneau J, et al. The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. *Hepatology* 2014;59:1. doi 10.1002/hep.26639.
- Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? *Antiviral Res* 2014;104:62– 72. doi.org/10.1016/j.antiviral.2014.01.002..
- Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo Gc. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. *Hepatololy* 1997;25:449-58. doi: 10.1002/hep.510250233.
- Cramp ME, Carucci P, Underhill J, Naoumov NV, William R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. *J Heatol* 1998;29:2,207-213. doi.org/10.1016/S0168-8278(98)80005-6.
- Weseslindtner L, Neumann-Haefelin C, Viazov S, Haberstroh A, Kletzmayr J, Aberle JH, et al. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. *J Hepatol* 2009;**50**:693-704. doi: 10.1016/j.jhep.2008.11.023.

## 326 Epidemiological and Clinical Factors Associated

- Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. *Gut* 2001;49:423-30. doi: 10.1136/gut.49.3.423.
- Rao HY, Sun DG, Jiang D, Yang RF, Guo F, wang JH, et al. IL28B Genetic Variants and Gender Are Associated With Spontaneous Clearance of Hepatitis C Virus Infection. *J Viral Hepat* 2012;19:173-81. doi: 10.1111/j.1365-2893.2011.01497.x.
- Bulteel N, Sarathy PP, Forrest E, Stanley AJ, Innes H, Mills PR, et al. Factors associated with spontaneous clearance of chronic hepatitis C virus infection. *J Hepatol* 2016;65:266– 272. doi: 10.1016/j.jhep.2016.04.030
- Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, et al. Spontaneous Clearance of Serum Hepatitis C Virus RNA During the Clinical Course of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C. *Hepatol Res* 2014;44:E32-7. doi: 10.1111/hepr.12203.
- Zein CO. Spontaneous clearance of chronic hepatitis C during pregnancy. *Am J Gastroenterol* 2001;96:3044-3045. doi: 10.1111/j.1572-0241.2001.04697.x.
- Sagneli E, Coppola N, Pisaturo M, Masielo A, Tonziello G, Sagneli C, et al. HBV Superinfection in HCV Chronic Carriers: A Disease That Is Frequently Severe but Associated With the Eradication of HCV. *Hepatology* 2009;49:1090-7. doi: 10.1002/hep.2279.
- Gruener NH, Jung MC, ulsenheimer A, Gerlach TJ, Diepolder HM, Schirren CA ,et al. Hepatitis C Virus Eradication Associated With Hepatitis B Virus Superinfection and Development of a Hepatitis B Virus Specific T Cell Response. *J Hepatol* 2002;**37**:866-9. doi: 10.1016/s0168-8278(02)00303-3.
- Maida I, Rios MJ, Perez-Saleme L, Ramos B, sariano V, Pegram PS, et al. Profile of Patients Triply Infected With HIV and the Hepatitis B and C Viruses in the HAART Era. *AIDS Res Hum Retroviruses* 2008;24:679-83. doi: 10.1089/ aid.2007.0240.
- Zucman D, De Truchis P, Ruel M, Berthe H, Olivier C. Guérison spontanée de l'hépatite chronique C chez 4 patients co-infectés par le VIH et le VHC : rôle de la restauration immunitaire sous trithérapie et de l'arrêt de la consommation d'alcool. *Médecine et maladies infectieuses* 2008;**38**:S167– S169. doi : 10.1016/S0399-077X(08)73175-5.
- Vispo E, Barreiro P, Plaza Z, Fernández-Montero J, Labarga P, et al. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. *AIDS* 2014; 28:1473–78. doi: 10.1097/QAD.0000000000275
- Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571–83. doi: 10.1016/S0140-6736(11)61097-
- 20. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and nat-

ural history of HCV infection *Nat Rev Gastroenterol Hepatol* 2013;**10**:553-562. doi: 10.1038/nrgastro.2013.107.

- Trinchet JC. Histoire naturelle de l'infection par le virus de l'hépatite C (conférence de consensus). *Gasroenterol clin Biol* 2002 ; 26 :B144-B153. doi : GCB-04-2002-26-HS2-0399-8320-101019-ART16
- Alter HJ, Conry-Cantelena C, Melpolder J, Van Raden M, Herion D, Lau D, et al. Hepatitis C in asymptomatic blood donors. *Hepatology* 1997;26(Suppl 1):29S-33S. doi: 10.1002/hep.510260705.
- Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of communityacquired hepatitis C infection in a cohort with sera stored from 1971-1975. *Hepatology* 2000;**32**:582-7. doi: 10.1053/ jhep.2000.9714.
- Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. *Can J Gastroenterol* 2007;21: 447-51. doi: 10.1155/2007/796325.
- Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, et al. Goedert. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. *Blood* 2006;**107**:3. doi: 10.1182/blood-2005-07-2781.
- 26. Tang S, Yue M, Wang J, Su J, Yu R, Zhou D, et al. Association of genetic variants in estrogen receptor alpha with HCV infection susceptibility and viral clearance in a high-risk Chinese population. *Eur J Clin Microbiol Infect Dis* 2014;**33**:999-1010. doi: 10.1007/s10096-013-2038-y.
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383–98. doi:10.1016/j.cld.2005.05.003.
- Marcellin P. Hepatitis C: The Clinical Spectrum of the Disease. J Hepatol 1999;31 Suppl 1:9-16. doi: 10.1016/s0168-8278(99)80368-7.
- Orland JR, Wright TL, Cooper S. Acute Hepatitis C. *Hepatology* 2001;**33**:321-7. doi: 10.1053/jhep.2001.22112.
- Alberti A, Chemello L, Benvegnu L. Natural History of Hepatitis C. J Hepatol 1999;31 Suppl 1:17-24. doi: 10.1016/ s0168-8278(99)80369-9.
- Kenny-Walsh E. Clinical outcomes after hepatitis c infection from contaminated anti-D immune globulin. *N Engl J Med* 1999;**340**:1228-33. doi: 10.1056/NEJM199904223401602.
- Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. *Annu Rev Immunol* 2001;19:65-91. doi: 10.1146/annurev.immunol.19.1.65.
- Roulot D, Vallet-Pichard A. Histoire naturelle et facteurs influençant la sévérité de l'infection chronique virale C au cours de la coinfection VIH-VHC. *Gastroenterol Clin Biol* 2007;**31**:881-6. doi: 10.1016/S0399-8320(07)73985-4
- Boodrama B, Hershowa RC, Cotlerb SJ, Ouellet LJ. Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug. *Drug Alcohol Depend* 2011;119: 166–171. doi:10.1016/j. drugalcdep.2011.06.005.

- Algouda M, Tissot-Duponte H, Menarde A, Botta-Fridlundd D, Aherfia S, Colsona P. Spontaneous clearance of chronic hepatitis C virus infection in HIV positive patients, southeastern France. *Clin Res Hepatol Gastroenterol* 2017;**41**,e87-e89. doi.org/10.1016/j.clinre.2017.04.005.
- Carvalho-Filho RJ, CA Feldner AC, Silva AEd, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. *World J Gastroenterol* 2015; 21: 408-22. doi: 10.3748/wjg.v21.i2.408.
- Lemos LB, Perez RM, Matos CA, Silva IS, Silva AE, Ferraz ML. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. *J Clin Gastroenterol* 2008;42: 208-211. doi: 10.1097/MCG.0b013e31802dc57f.
- Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. *J Gastroenterol Hepatol* 1998; 13: 62-7. doi: 10.1111/j.1440-1746.1998.tb00547.x.
- 39. Rouabhia S, Malek R, Bounecer H, Dekaken A, Bendali F, Sadelaoud M, et al. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. *World J Gastroenterol* 2010;16: 3427-31. doi:10.3748/wjg.v16. i27.3427.
- 40. Kabbaj N, Errabih I, Guédira M, El Atmani H, Benabed K, Al Hamany Z ,et al. Hepatitis C and diabetes mellitus: effect of diabetes on the course of the liver disease. *Ann Endocrinol* 2006 ;**67**:233-7. doi: AE-06-2006-67-3-0003-4266-101019-200507483.